← FDA DRUG APPROVALS

FDA ANDA · ANDA079141

TOLTERODINE TARTRATE

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA079141
TYPE
ANDA
ORIGINAL APPROVAL
2016-11-22
LATEST ACTION
2025-06-17
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

TOLTERODINE TARTRATEPrescription
TOLTERODINE TARTRATE 4MG · CAPSULE, EXTENDED RELEASE · ORAL
TOLTERODINE TARTRATEPrescription
TOLTERODINE TARTRATE 2MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2025-06-17Labeling · Supplement 14 · standardAP
2020-03-09Labeling · Supplement 1 · standardAP
2016-11-22OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →